[December 15, 2017] |
|
U.S. Doryx Promotional Report 2016-2017 - Research and Markets
The "Doryx
2016 U.S. Promotional Report" report has been added to Research
and Markets' offering.
The 5 Key Questions Addressed by this Report:
-
How many physicians were reached by Doryx through personal promotion
in 2016 and how does this compare to its peer set in the Acne markets?
-
What promotional mix was leveraged (e.g., sales rep detailing,
physician education, and paid speaking) and what was the median spend
on each type of activity?
-
How does Mayne's depth of coverage vary within key specialties (e.g.,
Dermatology) and how does this compare to its peers and the overall
set of rep-accessible physicians?
-
How often are physicians rceiving paid meals for Doryx throughout the
year (e.g., monthly, quarterly, annually)?
-
Who were the most detailed prescribers and top paid speakers for Doryx
in 2016?
Data Sources and Methodology:
-
We leverage company-reported financial transaction data disclosed
through CMS Open Payments. This data set captures all transfers of
value (e.g., speaking fees, consulting fees, travel, education, and
meals) made on behalf of a drug or device manufacturer to a physician.
Currently, 42 months of longitudinal data is available - covering
payments to more than 900,000 U.S. healthcare professionals.
-
Over 5,900 paid interactions across 2,000 physicians made on behalf of
Doryx were carefully examined to support our analysis. In addition,
interaction data from 14 peer products (e.g. Acanya, Aczone, Atralin
Gel, Avar, Clindacin, Clindagel, Differin, Epiduo, Morgidox, Neuac,
Onexton, Solodyn, Zenatane, and Ziana) was leveraged to provide
benchmarking and market insights.
For more information about this report visit https://www.researchandmarkets.com/research/x67pdg/u_s_doryx?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005564/en/
[ Back To TMCnet.com's Homepage ]
|